RedHill Biopharma Faces Nasdaq Delisting Risk

TL;DR

Nasdaq says RHBP's stock price is too low, needs to fix by April 2026 or get booted.

AI Summary

RedHill Biopharma Ltd. received a notification from the Nasdaq staff on October 22, 2025, indicating that the company is not in compliance with Nasdaq Listing Rule 5450(a)(1) due to its non-compliance with the minimum bid price requirement. The company has until April 20, 2026, to regain compliance.

Why It Matters

Failure to regain compliance could lead to RedHill Biopharma's securities being delisted from the Nasdaq Stock Market, potentially impacting its liquidity and investor confidence.

Risk Assessment

Risk Level: medium — The company is at risk of delisting from Nasdaq if it cannot meet the minimum bid price requirement by the specified deadline.

Key Numbers

• April 20, 2026 — Compliance Deadline (The date by which RedHill Biopharma must meet Nasdaq's minimum bid price requirement.)

Key Players & Entities

• RedHill Biopharma Ltd. (company) — The company filing the report and receiving the notification.
• Nasdaq (company) — The stock exchange that issued the non-compliance notification.
• October 22, 2025 (date) — The date the Nasdaq staff issued the notification.
• April 20, 2026 (date) — The deadline for RedHill Biopharma to regain compliance with Nasdaq rules.
• Nasdaq Listing Rule 5450(a)(1) (rule) — The specific rule RedHill Biopharma is currently not in compliance with.

FAQ

Key Financial Figures

• $2.5 million — holders' equity now exceeds the minimum $2.5 million requirement and that it is well positio
• $2.5 million — holders' equity now exceeds the minimum $2.5 million and that it is well positioned to maint

Filing Documents

• zk2533874.htm (6-K) — 29KB
• image00001.jpg (GRAPHIC) — 293KB
• 0001178913-25-003542.txt ( ) — 433KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: October 22, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer Press Release RedHill Biopharma Receives Nasdaq Staff Determination Notification On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1) -- Following RedHill's transaction with Cumberland Pharmaceuticals Inc., announced October 20, 2025, the Company believes that its stockholders' equity now exceeds the minimum $2.5 million requirement and that it is well positioned to maintain compliance -- The Company intends to appeal Staff's determination to a Hearings Panel, pursuant to the Nasdaq Listing Rule 5800 Series and present its case. The Panel has the authority to determine whether the Company has regained compliance or to grant up to a 180-day extension to regain compliance -- Submission of a hearing request will stay any delisting or suspension action of the Company's American Depositary Shares, and RedHill remains listed and traded on the Nasdaq Capital Market, pending the hearing -- There can be no assurance that the Panel will grant an extension of the compliance period or that the outcome of the hearing will be favorable to the Company TEL AVIV, Israel and RALEIGH, NC, October 22, 2025, RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on October 16, 2025, it received a Nasdaq Staff Determination letter indicating that the Company had not met the minimum stockholders' equity requirements ("Minimum Equity Requirement

Forward Looking Statements

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements include statements regarding the strategic transaction with Cumberland and are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that the Staff Determination Notification from the Nasdaq LLC may not be withdrawn and that the Company may be delisted from the Nasdaq Capital Market; the risk that the strategic transaction with Cumberland will not bring the currently anticipated benefits to RedHill's global Talicia business or to RedHill's financial position, costs or its broader strategic objectives; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed

View Full Filing

View this 6-K filing on SEC EDGAR